July 19 2013 | By Márcio Barra
The FDA has approved an intravenous formulation of the tumor necrosis factor inhibitor Simponi Aria (golimumab)for the treatment of moderate to severe rheumatoid arthritis in combination with methotrexate, according to manufacturer Janssen Biotech. This makes it the fourth approval for the drug since its initial approval in 2009, making it a strong contender for blockbuster status. The drug is already approved for active psoriatic arthritis, active ankylosing spondylitis, and moderate to severe ulcerative colitis unresponsive to previous treatments, the latter back in May 2013.
View original post 272 more words